{"filings":[{"id":1673123,"accession_number":"0001493152-26-033405","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2026-07-15T21:37:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"Stereotaxis completes Robocath acquisition; files risk factors highlighting dilution and integration risks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquisition closed July 7, 2026; issued 6,269,628 Closing Shares (including warrants) and up to $25M earnout.","Robocath has sustained historical operating losses; acquisition will not be accretive and will increase operating losses.","Extended $1.1M operating loans to Robocath between signing and closing, repaid at closing.","Earnout shares registered: up to 13,179,975 shares, capped at 19.9% of outstanding shares as of July 7, 2026.","Integration risks include manufacturing challenges, French labor laws, and conversion from French GAAP to U.S. GAAP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1535876,"accession_number":"0001493152-26-032598","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2026-07-09T12:13:39+00:00","items":["3.02","7.01","8.01","9.01"],"status":"ready","headline":"Stereotaxis completes acquisition of Robocath for ~$20M in cash and stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal valued at ~$20M in cash and common stock; earnout up to $25M based on regulatory/commercial milestones.","Issued 1,469,485 shares and 4,575,143 pre-funded warrants to Robocath shareholders at closing.","Robocath fully integrated into Stereotaxis, combining robotic platforms for electrophysiology, interventional cardiology, and neurointerventions.","Earnout consideration may be paid in cash or stock at Stereotaxis' election, capped at 19.9% of outstanding shares without stockholder approval.","Transaction closed July 7, 2026; resale registration statement for stock consideration to be filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":469118,"accession_number":"0001493152-26-023654","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2026-05-15T19:31:27+00:00","items":["5.07"],"status":"ready","headline":"Stereotaxis annual meeting results: all three proposals approved by shareholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elect David Benfer (52.2M for), Arun Menawat (49.5M for), Myriam Curet (52.7M for) as Class I directors.","Ratification of Ernst & Young as FY2026 auditor approved: 79.0M for, 112.6K against.","Advisory vote on executive compensation passed: 52.1M for, 985.4K against.","Quorum of ~65.3% of outstanding voting power represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40444,"accession_number":"0001493152-26-022488","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2026-05-12T20:10:47+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis reports Q1 revenue $6.3M, net loss $5.9M; guides FY26 rev >$40M; MAGiC FDA approved, Robocath acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.3M vs $7.5M YoY; net loss $5.9M; cash $14.6M, no debt.","MAGiC catheter (FDA approved Jan) and Synchrony system (FDA cleared Apr) now in commercial use.","Definitive agreement to acquire Robocath, combining complementary robotic technologies.","Guides FY26 revenue >$40M, double-digit growth; Q3 and Q4 each >$10M.","Manufacturing ramp for MAGiC targets 500/month by year end; winding down J&J relationship."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91948,"accession_number":"0001493152-26-016685","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Stereotaxis to acquire Robocath for $20M initial plus up to $25M in earnouts","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to $45M: $20M upfront (cash/stock) plus earnouts of $10M (FDA approval) and $15M (commercial milestones).","Expected close in July 2026, subject to French regulatory clearance and Stereotaxis debt restructuring.","Interim financing of approx. €1.3M provided to Robocath between signing and closing.","Stock consideration capped at 19.9% of outstanding shares pre-closing unless shareholder approval obtained.","Earnout targets based on next-gen interventional device FDA approval and specified product sales thresholds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102387,"accession_number":"0001493152-26-009366","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis reports Q4 2025 revenue $8.6M (+36% YoY); guides FY2026 revenue >$40M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $8.6M (+36% YoY); system rev $3.3M, recurring $5.3M.","Full year 2025 revenue $32.4M (+20% YoY); guidance for 2026 to surpass $40M.","Q4 net loss $5.5M vs $7.5M prior year; adjusted net loss $2.5M vs $3.6M.","Cash $13.4M, no debt; raised $3.1M in ATM offering at avg $3.17/share.","Key 2026 milestones: 5 GenesisX programs, ramp MAGiC to 500/month, FDA approval for Synchrony."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118655,"accession_number":"0001493152-25-021772","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Reports Q3 2025 Revenue of $7.5M, Net Loss $6.5M; Guides Q4 Revenue Above $9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue totaled $7.5M, with system revenue of $1.9M and recurring revenue of $5.6M.","Net loss was $6.5M; adjusted net loss excluding non-cash charges was $2.4M.","Cash and equivalents were $10.5M with no debt; additional $4M expected from July financing.","FDA clearance for GenesisX robotic system announced; MAGiC Sweep generated over $300k in first two months.","Q4 2025 revenue expected to exceed $9M, supporting annual revenue growth of over 20%."],"consensus_eps_estimate":-0.0612,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":23735000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135156,"accession_number":"0001641172-25-026031","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Stereotaxis enters ATM equity agreement to sell up to $50M of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Roth Capital Partners for at-the-market offering of up to $50M in common stock.","Proceeds to fund working capital, R&D, and accelerated commercialization of innovation pipeline.","Placement fee of up to 3.0% of gross sales; expense reimbursement up to $50k initial and $5k per quarter.","Shares sold under existing Form S-3 shelf registration (File No. 333-272102); company not obligated to sell."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135155,"accession_number":"0001641172-25-022580","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Q2 revenue surges 95% to $8.8M; net loss narrows to $3.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.8M (+95% YoY, +18% seq); system revenue $3.0M (vs $0.2M), recurring $5.8M (+35% YoY).","Net loss $3.8M vs $5.8M; adjusted net loss $1.3M vs $3.3M; gross margin 52%.","Cash $7.0M at June 30; July $12.5M financing closed; pro forma cash $18.8M, no debt.","Guidance: double-digit FY2025 revenue growth; Q4 recurring ~$7M; system $2-3M/quarter.","FDA clearance for MAGiC Sweep catheter; initial sales in Q2; further approvals expected near-term."],"consensus_eps_estimate":-0.0663,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":16270000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135154,"accession_number":"0001641172-25-019990","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Stereotaxis announces $12.5M registered direct offering at $2.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $12.5M from sale of common stock at $2.00/share; initial closing of $8.5M (4.25M shares) expected July 18, 2025.","Second closing of $4.0M (2M shares) scheduled on or before November 25, 2025.","Offering led by strategic industry partner and institutional investors; Lake Street Capital Markets as placement agent.","Proceeds to accelerate product commercialization, R&D, and working capital.","Placement agent receives 5.5% cash fee on $7.5M of initial proceeds, plus expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135153,"accession_number":"0001641172-25-019985","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Stereotaxis pre-announces Q2 revenue $8.5-8.8M, up 90% YoY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue expected between $8.5M and $8.8M for Q2 2025, up ~15% sequentially and 90% YoY.","Growth driven by both recurring and system revenues; gross margins at or above Q1 2025 levels.","GAAP operating expenses estimated in the range of $8.2M to $8.8M.","Full Q2 financial results and earnings call scheduled for August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152127,"accession_number":"0001641172-25-011415","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stereotaxis annual meeting elects directors Fischel and Levin, ratifies EY","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 59% achieved with 63.8M shares represented out of 85.98M common plus 21.66M Series A votes.","Dr. Nathan Fischel elected with 43.0M votes for, 2.2M withheld; Ross B. Levin elected with 42.3M for, 3.0M withheld.","Ernst & Young ratified as independent auditor for FY2025 with 63.6M votes for, 0.13M against, 0.04M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152126,"accession_number":"0001641172-25-009667","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Q1 revenue $7.5M (+9% YoY); recurring up 29%; operating loss widens to $5.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.5M (+9% YoY); system revenue $2.0M, recurring revenue $5.5M (+29% driven by Map-iT catheters).","Operating loss ($5.9M) vs ($4.7M) prior year; net loss ($5.8M) vs ($4.5M). Adjusted operating loss ($2.7M).","Cash $10.7M, no debt; free cash flow negative ($1.8M), improved from ($2.3M) YoY.","Reiterates FY 2025 double-digit revenue growth; expects recurring revenue to scale to $7M in Q4.","First GenesisX order received; initial MAGiC commercialization in Europe; six active regulatory reviews."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":7472000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170951,"accession_number":"0001493152-25-008810","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q4 revenue up 39% to $6.3M; expects double-digit revenue growth in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $6.3M (+39% YoY); full year $26.9M (+0.4% YoY).","Operating loss ($7.6M) in Q4; adjusted operating loss ($4.0M); net loss ($7.5M).","Cash $12.4M, no debt; positive free cash flow of $1.3M in Q4.","2025 guidance: double-digit revenue growth; recurring revenue to scale from $5M Q1 to $7M Q4.","Regulatory milestones: European MAGiC catheter approval, GenesisX first sale, China approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187911,"accession_number":"0001493152-24-044573","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Q3 revenue $9.2M, up 18% YoY; net loss $6.2M; cash $13.3M at Oct end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.2M (+18% YoY); system revenue $4.4M, recurring $4.8M.","Net loss $6.2M, adjusted net loss $3.0M; negative free cash flow ($4.2M) in Q3.","Received orders for two Genesis systems; system backlog >$15M supports growth.","Cash $13.3M at Oct end (up from $11.0M Sep 30); expects ~$12M year-end, no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":20578000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204431,"accession_number":"0001493152-24-031266","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Q2 revenue down 43% to $4.5M; net loss $5.8M; expects H2 revenue >$14M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $4.5M vs $7.9M prior year; system revenue $0.2M due to hospital construction delays.","Net loss $5.8M, adjusted net loss $3.3M; operating loss $6.0M, adjusted $3.5M.","Cash and cash equivalents $15.2M at June 30, 2024, no debt; year-end cash target ~$13M.","CE mark obtained for GenesisX, 510(k) submitted in US; acquisition of Access Point Technologies closed.","Full-year revenue expected approximately equal to prior year; H2 revenue >$14M from stable recurring and Genesis shipments."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":11382000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204430,"accession_number":"0001493152-24-029986","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Stereotaxis closes acquisition of Access Point Technologies, issues 1.49M shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Access Point Technologies EP, Inc. (APT) completed on July 31, 2024.","Issued 1,486,620 shares of common stock as upfront stock consideration.","APT designs and manufactures diagnostic catheters for cardiac ablation, sold globally.","Shares issued in private placement under Section 4(a)(2) and Rule 506 of Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204429,"accession_number":"0001493152-24-028364","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Stereotaxis appoints Nachum Shamir to board; former Luminex, Given Imaging CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nachum 'Homi' Shamir elected to Stereotaxis Board of Directors effective July 18, 2024.","Shamir previously led Luminex (sold for $1.8B) and Given Imaging (sold for $1B).","Brings expertise in growing global commercial operations and medical device M&A.","Currently serves as Chairman of Mediwound and SSI Diagnostica.","Will receive compensation on same basis as other non-management directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221214,"accession_number":"0001493152-24-020281","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["1.01","3.02","5.07"],"status":"ready","headline":"Stereotaxis acquires APT for stock; earnouts based on revenue & regulatory milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires APT, a diagnostic catheter maker, for stock consideration; earnouts tied to global revenue and US/EU regulatory milestones for robotically-navigated catheters.","Upfront stock consideration ~6.1M shares (~25% of total); closing expected Q3 2024 subject to APT shareholder approval and debt restructuring.","APT must pay Stereotaxis a $1.0M termination fee if it breaches non-solicitation restrictions.","At annual meeting, shareholders re-elected David Fischel, ratified Ernst & Young, approved +4M shares for stock plan and +250K shares for ESPP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221213,"accession_number":"0001493152-24-018881","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Stereotaxis Q1 revenue $6.9M (+5% YoY); acquires Access Point Technologies for stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 revenue $6.9M (+5% YoY); system revenue $2.6M, recurring $4.3M.","Net loss $4.5M; adjusted net loss $1.9M; free cash flow -$2.3M.","Acquires APT (electrophysiology catheters) for stock; upfront + contingent milestone payments.","APT expected to contribute ~$5M annual revenue in first year post-close; close expected Q3 2024.","Regulatory submissions for MAGiC catheter in US/Europe; smaller robot submissions expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240781,"accession_number":"0001493152-24-008704","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Q4 revenue $4.6M, down 37% YoY; full year adjusted net loss $10.2M; guides Q1 2024 revenue ~$7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $4.6M vs $7.3M prior year; full year revenue $26.8M vs $28.1M.","Q4 net loss $5.0M; full year adjusted net loss $10.2M vs $7.8M prior year.","Cash $20.6M; no debt; system backlog $14.7M entering 2024.","Q1 2024 revenue guidance ~$7.0M; expects double-digit revenue growth for full year 2024.","Regulatory submissions for robotic catheter in US/Europe; smaller robot pending EU clearance mid-2024; guidewire launch in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258277,"accession_number":"0001493152-23-040008","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Q3 revenue $7.8M (+1% YoY); net loss $5.4M; cash $23M, no debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["System revenue $3.5M from 2 Genesis systems; recurring revenue $4.3M (down 19% YoY, lost catheter royalties).","Gross margin 52%; operating loss $5.6M vs $5.1M a year ago; adjusted operating loss $3.0M.","Cash and equivalents $23.0M at Sept 30, 2023; no debt; negative free cash flow $1.0M in Q3.","Expects to submit PMA supplement for MAGiC ablation catheter before year-end.","System backlog $13M; expects continued revenue growth in coming quarters."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":22206000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275578,"accession_number":"0001493152-23-027465","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Q2 revenue $7.9M (+28% YoY), net loss $5.0M, cash $23.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.9M, up 28% YoY; system revenue $3.3M (two Genesis systems), recurring revenue $4.6M.","Gross margin 53%; operating loss ($5.3M), net loss ($5.0M); adjusted net loss ($2.4M).","Cash $23.9M, no debt; expects year-end cash $22-24M; no additional financing needed.","Orders for two Genesis systems in Q2; system backlog $16M; guidance of double-digit revenue growth in 2023.","Announced strategic Abbott collaboration for EnSite X integration; MAGiC catheter study submitted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":14407000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293105,"accession_number":"0001493152-23-021433","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Stereotaxis to initiate first-in-human trial for MAGiC catheter after CE Mark clinical data request","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notified body requests clinical data for MAGiC catheter CE Mark under EU MDR; prior submission included preclinical data.","First-in-human trial to commence to support CE Mark; Stereotaxis expects to complete study before end of 2023.","Company reiterates expectation of double-digit revenue growth in 2023; strong cash position.","CEO states innovation strategy includes accessible robot and proprietary catheters for EP and endovascular interventions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293104,"accession_number":"0001493152-23-018391","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stereotaxis shareholders elect three directors, ratify EY, approve say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David W. Benfer elected with 39,528,692 votes for; Myriam Curet and Arun Menawat also elected.","Ratification of Ernst & Young as auditor passed with 64,193,577 for, 283,410 against.","Non-binding advisory vote on executive compensation approved: 38,666,726 for, 3,439,809 against.","Shareholders recommended future say-on-pay frequency of three years (27,754,457 votes for 3 years).","Meeting had 67% quorum; 64,591,746 shares represented out of 75,055,484 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293103,"accession_number":"0001493152-23-015876","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Q1 revenue $6.5M, net loss $5.3M; reiterates double-digit growth outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.5M vs $7.0M prior year; excluding catheter royalties, essentially flat.","Net loss $5.3M vs $4.1M; adjusted net loss (excl stock comp) $2.7M vs $1.6M.","Gross margin 59%; recurring revenue gross margin 79%, system margin 7% on low volumes.","Cash $26.8M with no debt; year-end cash expected $22-24M; sees double-digit revenue growth in 2023.","Orders received for two Genesis systems; expects increase in system orders vs 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":6548000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313749,"accession_number":"0001493152-23-006634","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis 2022 revenue $28.1M (-20% YoY); net loss $4.2M in Q4; guides double-digit growth in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $7.3M (down from $8.2M); full year revenue $28.1M (down from $35.0M).","Full year system revenue $6.8M (down from $11.2M); recurring revenue $21.3M (down from $22.9M).","Q4 net loss $4.2M vs $3.4M prior year; adjusted net loss full year $7.8M vs $1.4M prior year.","Cash and investments $29.7M, no debt; system backlog $14.8M entering 2023.","Expects double-digit revenue growth in 2023, driven by system backlog and new orders; no material contribution from new tech yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332214,"accession_number":"0001493152-22-031248","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Q3 2022 revenue $7.7M (-15% YoY); net loss widens to $4.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 revenue $7.7M vs $9.1M prior year; system rev $2.4M, recurring $5.3M.","Operating loss $5.1M, net loss $4.9M (prior year $4.6M); adjusted net loss $2.2M.","Cash and equivalents $32.4M, no debt; system backlog over $13M.","CE Mark submission for MAGiC catheter under technical review; next-gen robot launch expected summer 2023.","Expects year-over-year revenue growth in coming quarters; no additional financing needed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":20846000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349677,"accession_number":"0001493152-22-021705","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Q2 revenue $6.2M, down 32% YoY; net loss $5.2M; cash $35.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.2M vs $9.1M YoY; system revenue $0.6M, recurring $5.6M.","Net loss $5.2M; prior-year net loss $1.2M included $2.2M PPP loan forgiveness.","Adjusted net loss (excl. stock comp) $2.5M; operating expenses $9.8M.","Cash $35.1M, no debt; expects year-end cash ~$32M; no additional financing needed.","Backlog over $12M supports 2022 revenue growth guidance; cautious on hospital construction timelines."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":13189000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366701,"accession_number":"0001493152-22-014487","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2022-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stereotaxis shareholders elect directors, approve stock plans at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Nathan Fischel (48.8M for) and Ross Levin (47.1M for) as Class III directors to serve until 2025.","Ratified Ernst & Young as independent auditor for FY 2022 with 71.0M votes for, 332K against.","Approved 2022 Stock Incentive Plan (48.6M for, 4.1M against, 62K abstain).","Approved 2022 Employee Stock Purchase Plan (52.2M for, 562K against, 27K abstain).","All proposals passed; quorum of 75% (71.4M shares represented)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366700,"accession_number":"0001493152-22-012628","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Q1 revenue down 19% to $7.0M; net loss widens to $4.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.0M vs $8.6M prior year; system revenue $1.6M, recurring $5.4M.","Operating loss and net loss both ($4.1M) vs ($1.5M) prior year; adjusted net loss ($1.6M) vs ($0.1M).","Cash $36.9M, no debt; negative free cash flow ($3.3M) in Q1.","Reiterates revenue growth guidance; system revenue expected in H2; Genesis adoption driver.","Gross margin ~70%; recurring 85% consistent; system 21% reflects low volumes."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":7037000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386110,"accession_number":"0001493152-22-005899","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis reports 32% revenue growth in FY2021; adjusted net loss widens to $1.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2021 revenue $35.0M (up 32% from $26.6M); Q4 revenue $8.2M (up 21%).","System revenue rose to $11.2M in FY2021 from $3.6M; recurring revenue $22.9M (+4%).","Q4 net loss $3.4M vs $1.2M a year ago; full-year adjusted net loss $1.4M vs $3.5M.","Adjusted operating expenses $26.9M (FY2021) vs $22.6M; negative free cash flow $4.3M.","Cash $40.1M, no debt; expects continued revenue growth in 2022 with system revenue in H2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404027,"accession_number":"0001493152-21-027938","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Q3 revenue $9.1M (+5% YoY); operating loss widens to $4.6M; sees 2022 system revenue doubling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.1M (system $3.5M, recurring $5.3M); gross margin 52% with system margin 5% and recurring 86%.","Operating loss and net loss both ($4.6M) vs ($1.6M) a year ago; adjusted operating loss ($2.0M) vs ($0.8M).","Cash and equivalents $42.8M at Sept 30, 2021; expects to start 2022 with >$40M cash.","Maintains 2021 system revenue guidance of ~$11M; targets double-digit overall growth in 2022 with system revenue doubling.","Received orders for two Genesis systems; announced strategic collaboration with MicroPort EP in China."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":26780432.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422996,"accession_number":"0001493152-21-021450","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2021-08-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Stereotaxis agrees to pay $675K to settle shareholder lawsuit over proxy disclosures","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Putative class action filed by Richard Barre alleged fiduciary duty breaches for CEO Performance Award proxy disclosure deficiencies.","Company filed proxy supplement on May 10, 2021 to address claims without admitting liability.","Plaintiff voluntarily dismissed action on May 12, 2021; Chancery Court retained jurisdiction for fees.","Stereotaxis agreed to pay $675,000 to plaintiff's counsel for attorneys' fees and expenses in full satisfaction.","Payment resolves all claims for fees; Chancery Court not asked to review reasonableness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422995,"accession_number":"0001493152-21-019112","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stereotaxis Q2 revenue $9.1M (+70% YoY); sees system revenue doubling in 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue up ~70% YoY to $9.1M; system revenue $2.7M, recurring $6.1M.","Operating loss $3.4M, net loss $1.2M; adjusted net income $1.6M excluding stock comp.","Cash $44.2M; free cash flow negative $0.1M vs negative $1.2M prior year.","Received two robotic system orders (U.S. and Beijing); expects ~$11M system revenue in 2021.","Guidance: system revenue doubling in 2022; magnetic ablation catheter regulatory submissions in early 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":17673980.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422994,"accession_number":"0001493152-21-017714","cik":1289340,"company_name":"Stereotaxis, Inc.","ticker":"STXS","form_type":"8-K","filed_at":"2021-07-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Stereotaxis appoints Myriam Curet, Intuitive Surgical CMO, to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Myriam J. Curet, M.D., to Board effective July 22, 2021.","Dr. Curet is EVP and Chief Medical Officer at Intuitive Surgical, a pioneer in robotic surgery.","She has served as Clinical Professor of Surgery at Stanford since 2000.","Compensation is same as other non-management directors; no material transactions with her."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":200848921.5671642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}